← Leaderboards
Stacy Remiszewski
Evrys Bio, Llc
$11,617,185
Attributed
$11,617,185
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,617,185 · 4
By mechanism
R44$11,392,186 · 3
R43$224,999 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Sirtuins”
- Eric M Verdin · J. David Gladstone Institutes$16,329,641
- David A. Sinclair · Harvard University (Medical School)$9,992,497
- Mahesh P Gupta · University Of Chicago$9,367,283
- John M Denu · Oregon Health And Science University$9,140,548
- Jorge C Escalante · University Of Wisconsin Madison$7,411,058
- Sigrid C Veasey · University Of Pennsylvania$7,143,210
Research focus
SirtuinsVirusPharmaceutical PreparationsViralIn VitroBiological AvailabilityIn VivoCytomegalovirusDoseFamilyRegimenCellsLeadProteinsInfluenza A VirusEffectivenessAntiviral AgentsVirus DiseasesSeriesOralVirus ReplicationMouse ModelResistanceDrug Resistance
Grant awards (14)
A single antiviral to treat multiple opportunistic infections$978,771
R44 · FY2025 · AI · contact PI
Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure$961,797
R44 · FY2025 · AI · contact PI
A single antiviral to treat multiple opportunistic infections$983,882
R44 · FY2024 · AI · contact PI
Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure$961,797
R44 · FY2024 · AI · contact PI
A single antiviral to treat multiple opportunistic infections$999,998
R44 · FY2023 · AI · contact PI
A single antiviral to treat multiple opportunistic infections$1,000,000
R44 · FY2021 · AI · contact PI
Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure$300,000
R44 · FY2021 · AI · contact PI
A single antiviral to treat multiple opportunistic infections$1,000,000
R44 · FY2020 · AI · contact PI
A single antiviral to treat multiple opportunistic infections$901,086
R44 · FY2020 · AI · contact PI
SIRTUIN AGONISTS AS PAN INFLUENZA ANTIVIRALS$1,000,000
R44 · FY2019 · AI · contact PI
A single antiviral to treat multiple opportunistic infections$999,997
R44 · FY2019 · AI · contact PI
SIRTUIN AGONISTS AS PAN INFLUENZA ANTIVIRALS$1,000,000
R44 · FY2018 · AI · contact PI
SIRTUIN AGONISTS AS PAN INFLUENZA ANTIVIRALS$304,858
R44 · FY2016 · AI · contact PI
An Antiviral to Treat Progressive Multifocal Leukoencephalopathy_(PML)$224,999
R43 · FY2015 · AI · contact PI